- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00092807
Sitosterolemia Extension Study (0653-003)(COMPLETED)
February 4, 2022 updated by: Organon and Co
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia - 1 Year Open-Label Extension
This is an extension study for patients having unusually high absorption of non-cholesterol sterols, resulting in heart-related diseases.
This study will evaluate the long term safety and the ability to lower cholesterol levels with an investigational drug.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The duration of treatment is 52 weeks.
Study Type
Interventional
Enrollment (Actual)
37
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with elevated sitosterol levels while taking current medication
Exclusion Criteria:
- Patient has a condition which, in the opinion of the investigator, might pose a risk to the patient, interfere with participation in the study, or does not meet the additional criteria as required by the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To assess the percent change relative to baseline in plasma sitosterol concentration after long-term treatment with MK0653 10 mg/day.
|
Secondary Outcome Measures
Outcome Measure |
---|
Assess the percent change relative to baseline in LDL-C/plasma campesterol concentrations, and safety and tolerability after long-term treatment with MK0653 10 mg/day in patients with homozygous sitosterolemia
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 12, 2001
Primary Completion (Actual)
September 18, 2001
Study Completion (Actual)
November 30, 2004
Study Registration Dates
First Submitted
September 23, 2004
First Submitted That Met QC Criteria
September 27, 2004
First Posted (Estimate)
September 28, 2004
Study Record Updates
Last Update Posted (Actual)
February 16, 2022
Last Update Submitted That Met QC Criteria
February 4, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Metabolic Diseases
- Genetic Diseases, Inborn
- Lipid Metabolism Disorders
- Heart Diseases
- Metabolism, Inborn Errors
- Lipid Metabolism, Inborn Errors
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Ezetimibe
Other Study ID Numbers
- P02257
- 2004_032
Plan for Individual participant data (IPD)
Study Data/Documents
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Disease
-
Centre Chirurgical Marie LannelongueActive, not recruitingValvular Heart Disease | Valve Disease, Heart
-
Yonsei UniversityCompletedMitral Valvular Heart Disease
-
University of PennsylvaniaCompleted
-
Abbott Medical DevicesRecruitingAortic Valve Disease | Valvular Heart DiseaseChina
-
Mansoura UniversitySuspendedValve Heart Disease | Elective Cesarean DeliveryEgypt
-
Assiut UniversityCompleted
-
Tulane UniversityCompletedCardiomyopathies | Valvular Heart Disease | Pericardial DiseaseUnited States
-
InnovHeartActive, not recruitingHeart Valve Diseases | Mitral Regurgitation | Valve Heart Disease | Mitral Valve Disease | Mitral DiseaseLithuania, Denmark, Hungary
-
Fundació Institut de Recerca de l'Hospital de la...UnknownValvular Heart Disease | Cardiac Disease | Nurse's Role | CompetenceSpain
-
Aarhus University Hospital SkejbyInstitute for Clinical and Experimental MedicineCompletedHeart Failure | Coronary Heart Disease | Ischemic Heart DiseasesDenmark
Clinical Trials on Comparator: placebo
-
Eisai Inc.CompletedAlzheimer's DiseaseUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Merck Sharp & Dohme LLCTerminated
-
Merck Sharp & Dohme LLCWithdrawn
-
Merck Sharp & Dohme LLCTerminated
-
TiumBio Co., Ltd.RecruitingEndometriosisCzechia, Italy, Russian Federation, Poland, Ukraine
-
Merck Sharp & Dohme LLCTerminatedType 2 Diabetes
-
Cognition TherapeuticsRecruitingAge-Related Macular DegenerationUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted